INFINITY PHARMACEUTICALS, INC.

Form 3 July 29, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement INFINITY PHARMACEUTICALS, INC. [INFI] Tasker Seth A (Month/Day/Year) 07/22/2016 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O INFINITY (Check all applicable) PHARMACEUTICALS, INC.. 784 MEMORIAL 10% Owner Director DRIVE _X__ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group General Counsel Filing(Check Applicable Line) _X_ Form filed by One Reporting Person CAMBRIDGE, MAÂ 02139 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) (Instr. 5) Form: Direct (D) or Indirect (Instr. 5) Common Stock Ι 3,525.45 By 401(k) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly.

Persons who respond to the collection of

information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

3. Title and Amount of 6. Nature of Indirect 1. Title of Derivative 2. Date Exercisable and Beneficial Security **Expiration Date** Securities Underlying Conversion Ownership (Month/Day/Year) (Instr. 4) Derivative Security or Exercise Form of Ownership

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 3

			(Instr. 4)		Price of	Derivative	(Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	12/04/2008(1)	12/04/2018	Common Stock	1,190	\$ 7.18	D	Â
Stock Option (Right to Buy)	01/05/2010(2)	01/05/2020	Common Stock	631	\$ 6.25	D	Â
Stock Option (Right to Buy)	03/09/2010(2)	03/09/2020	Common Stock	2,000	\$ 6.39	D	Â
Stock Option (Right to Buy)	01/06/2011(2)	01/06/2021	Common Stock	1,713	\$ 5.94	D	Â
Stock Option (Right to Buy)	01/06/2012(2)	01/06/2022	Common Stock	2,240	\$ 7.93	D	Â
Stock Option (Right to Buy)	(3)	08/14/2022	Common Stock	1,000	\$ 16.57	D	Â
Stock Option (Right to Buy)	(4)	01/04/2023	Common Stock	4,730	\$ 36.85	D	Â
Stock Option (Right to Buy)	(5)	03/06/2023	Common Stock	2,000	\$ 45.24	D	Â
Stock Option (Right to Buy)	(6)	01/10/2024	Common Stock	6,711	\$ 12.91	D	Â
Stock Option (Right to Buy)	(7)	08/25/2024	Common Stock	10,000	\$ 11.24	D	Â
Stock Option (Right to Buy)	(8)	01/14/2025	Common Stock	8,214	\$ 15.74	D	Â
Stock Option (Right to Buy)	(9)	03/19/2025	Common Stock	5,300	\$ 16.53	D	Â
Stock Option (Right to Buy)	(10)	01/06/2026	Common Stock	11,938	\$ 6.71	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Tasker Seth A C/O INFINITY PHARMACEUTICALS, INC. 784 MEMORIAL DRIVE CAMBRIDGE, MA 02139	Â	Â	General Counsel	Â	

Reporting Owners 2

Signatures

/s/ Seth A. 07/29/2016 Tasker

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vested as to 12/48th of the shares on December 4, 2008 and vested as to 1/48th of the shares at the end of each calendar month thereafter. The option has fully vested.
- (2) The option vested in equal monthly installments over four years beginning at the end of the calendar month during which the grant was made. The option has fully vested.
- (3) The option vests as to 1/48th of the shares on August 31, 2012 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
- (4) The option vests as to 1/48th of the shares on January 31, 2013 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
- (5) The option vests as to 1/48th of the shares on March 31, 2013 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
- (6) The option vests as to 1/48th of the shares on January 31, 2014 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
- (7) The option vests as to 1/48th of the shares on August 31, 2014 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
- (8) The option vests as to 1/48th of the shares on January 31, 2015 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
- (9) The option vests as to 1/48th of the shares on March 31, 2015 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
- (10) The option vests as to 1/48th of the shares on January 31, 2016 and vests as to 1/48th of the shares at the end of each calendar month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3